Last Updated : June 16, 2023
Effective July 17, 2023, CADTH Scientific Advice will implement a new fee range of CA$80,000 to CA$125,000 to continue its offerings on a cost-recovery basis.
CADTH provides high-quality, thoughtfully considered scientific advice that is informed, specific, timely, and fit for purpose. Early engagement provides an opportunity for pharmaceutical companies to gain a better understanding of CADTH’s perspectives on the proposed clinical development plans, including real-world evidence (RWE)–generation plans, and economic modelling plans.
The fee for this service is determined on a cost-recovery basis and includes a dedicated CADTH project team, as well as the engagement of leading clinical expert(s), a past member of CADTH’s drug expert committee, and in-house health economics experts. Sponsors also benefit from open dialogue during the Scientific Advice meeting and a written Record of Scientific Advice. For more details please refer to Standard CADTH Scientific Advice Process.
The fee for CADTH Scientific Advice ranges from $80,000 to $125,000 based on the scale of the project. All fees are in Canadian dollars and are subject to applicable taxes (GST, HST, or QST). The total fee will be determined following the submission of the Briefing Book. A representative of the CADTH Scientific Advice program will contact you once the submission is assessed to indicate the total fee and issue the final fee schedule. Please refer to the Fee Schedule for Scientific Advice for detailed information on fee payment for this service.